Ruotuo Bio

Ruotuo Bio is a private Shanghai-based biopharmaceutical company focused on innovative therapeutics for oncology and autoimmune diseases. The company appears to operate dual R&D capabilities in Shanghai and the San Francisco Bay Area and emphasizes antibody therapeutics, antibody-drug conjugates, and cytokine-related platform technologies. Publicly available sources indicate that Ruotuo Bio uses its ExenokinesTM cytokine platform together with ADC technology to advance internally owned programs, with patent activity reported around HER2-targeting ADCs. The company completed an equity financing in 2023, with Shanghai Junshi Biosciences becoming its largest shareholder at just under 49%. Overall, Ruotuo Bio looks like an early-stage Chinese biotech building a biologics-focused pipeline in cancer and immune-mediated disease.